Dyadic and Scripps Research collaborate on hantavirus antibody and vaccine development using C1 platform

DYADIC INTERNATIONAL INC

Collaboration to evaluate monoclonal antibody and vaccine candidates targeting hantaviruses, including Andes virus causing Hantavirus Pulmonary Syndrome.
Builds on prior Andes virus monoclonal antibody work; C1 platform aims for rapid, scalable biologic production.
C1 platform previously applied to RSV, malaria, Andes, Ebola, Marburg; demonstrated comparable neutralization to mammalian systems.
Dyadic currently in funded collaborations with Gates Foundation, CEPI, and FBS for accelerating vaccine/antibody development.
Parties plan to explore external partnership and non-dilutive funding opportunities to support further development.

This headline and bullets were generated automatically by deepseek-v4-flash:cloud@v2 from the public filing. Read the source on SEC.gov before relying on any specific claim. Not investment advice. See methodology for how this pipeline works.